Staff Reports
The political theater over the abortion pill just turned into a last‑minute plea at the gates of the Justice Department. Fourteen women, led by Susan B. Anthony Pro‑Life America, delivered a letter to Acting U.S. Attorney General Todd Blanche asking him to stop defending the Food and Drug Administration’s mail‑order mifepristone policy and to settle the lawsuit in favor of the plaintiffs. This appeal lands not as gentle advice but as a deadline: the letter was sent just ahead of Blanche’s Senate Judiciary Committee confirmation hearing on July 15–16, 2026.
What the letter is asking — plain and simple
The women want the Department of Justice to stop defending the FDA’s 2023 REMS change that opened the door to telehealth and mail distribution of mifepristone. They ask for a consent decree or settlement that would halt mail‑order abortion pills while the agency completes a safety review. Their claim: mail distribution makes coercion, trafficking, and misuse easier and has real victims. Rosalie Markezich’s case is at the center of the litigation — she says pills were prescribed without an in‑person visit and ended her pregnancy against her will. The letter uses that kind of story to turn an abstract legal fight into a human one.
Why the timing is not an accident
This was not a coincidence. The letter arrived the week before Blanche’s confirmation hearing. Pro‑life groups want him on record: Will the DOJ defend the FDA’s policy or will he change course and protect women from mail‑order mifepristone? Senators on the Judiciary Committee, including those who have already signaled interest in the case, are likely to press him. That makes the request both legal and political — exactly the kind of pressure a confirmation process is built to produce.
Legal stakes and practical consequences
The case, styled Markezich v. FDA, is moving fast. The Fifth Circuit has already issued emergency orders and set an expedited appellate schedule. If the DOJ withdraws its defense or settles, it would immediately curtail nationwide access to mail‑order mifepristone and spark new rounds of litigation from drugmakers and abortion‑rights groups. If DOJ keeps defending the FDA, the appeals process — and possibly the Supreme Court — will decide the near‑term future of the abortion pill. Either way, an answer from Blanche will shape access across the country.
Acting Attorney General Blanche now faces a clear choice. He can follow the Department’s current line and defend a policy many say removes commonsense safeguards, or he can listen to the women who say they were harmed and negotiate a settlement that restores in‑person checks while the FDA completes its review. Senators should ask plain questions at his hearing, and Blanche should give plain answers. This is about law, safety, and common sense — not spin. If he wants to avoid being the man who defended a policy that let pills be mailed into coercive hands, he’ll settle. And if he does not, conservatives should be ready to hold him accountable in public and on the bench.
